A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
A Phase IIb, Multicenter, Double-blind, Placebo-controlled Induction Study With an Active Treatment Extension to Assess the Efficacy, Safety, and Pharmacokinetics of RO7837195 in Patients With Moderately to Severely Active Ulcerative Colitis
2 other identifiers
interventional
224
14 countries
82
Brief Summary
The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Sep 2025
Typical duration for phase_2
82 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 15, 2025
CompletedFirst Posted
Study publicly available on registry
May 18, 2025
CompletedStudy Start
First participant enrolled
September 29, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 25, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 31, 2028
May 4, 2026
May 1, 2026
1.9 years
May 15, 2025
May 1, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage of Participants With Clinical Remission at Week 12
Clinical remission is defined as the Modified Mayo Score (mMS) of ≤ 2, including stool frequency subscore of ≤ 1, rectal bleeding subscore of 0, and endoscopy subscore of ≤ 1.
At Week 12
Secondary Outcomes (6)
Percentage of Participants With Clinical Response at Week 12
At Week 12
Percentage of Participants With Endoscopic Improvement at Week 12
At Week 12
Percentage of Participants With Endoscopic Remission at Week 12
At Week 12
Number of Participants With Adverse Events (AEs)
Up to Weeks 65
Serum Concentration of RO7837195
Up to Weeks 65
- +1 more secondary outcomes
Study Arms (5)
RO7837195 Dose Regimen 1
EXPERIMENTALParticipants will receive RO7837195 per the pre-defined dosing regimen during the 12-week induction and 40-week active treatment extension phases.
RO7837195 Dose Regimen 2
EXPERIMENTALParticipants will receive RO7837195 per the pre-defined dosing regimen during the 12-week induction and 40-week active treatment extension phases.
RO7837195 Dose Regimen 3
EXPERIMENTALParticipants will receive RO7837195 per the pre-defined dosing regimen during the 12-week induction and 40-week active treatment extension phases.
RO7837195 Dose Regimen 4
EXPERIMENTALParticipants will receive RO7837195 per the pre-defined dosing regimen during the 12-week induction and 40-week active treatment extension phases.
RO7837195 Matched Placebo/ RO7837195
EXPERIMENTALParticipants will receive RO7837195 matched placebo and RO7837195 per the pre-defined dosing regimen during the 12-week induction and 40-week active treatment extension phases, respectively.
Interventions
RO7837195 will be administered as per the schedule specified in the protocol.
RO7837195 matched placebo will be administered as per the schedule specified in the protocol.
Eligibility Criteria
You may qualify if:
- Diagnosis of ulcerative colitis (UC) established at least 3 months
- Moderately to severely active UC assessed by mMS
- Inadequate response, loss of response, or intolerance to conventional or advanced therapies for UC
You may not qualify if:
- Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC
- Diagnosis of Crohn's disease or indeterminate colitis
- Treatment with an advanced therapy targeted at tumor necrosis factor-like cytokine 1A (TL1a)
- Inadequate response, loss of response, or intolerance to treatment of UC with an advanced therapy targeted at IL-12 and/or IL-23
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Genentech, Inc.lead
Study Sites (82)
Gastro Care Institute
Lancaster, California, 93534, United States
Medical Associates Research Group, Inc.
San Diego, California, 92123, United States
Peak Gastroenterology Associates
Colorado Springs, Colorado, 80907, United States
Clinical Research of Osceola, LLC
Kissimmee, Florida, 34741, United States
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
Intercity Gastroenterology
Fresh Meadows, New York, 11366, United States
Monroe Biomedical Research
Monroe, North Carolina, 28112, United States
Mater Misericordiae Ltd
South Brisbane, Queensland, 4101, Australia
Chronos Pesquisa Clinica
Brasília, Federal District, 72145-450, Brazil
Hospital Felicio Rocho
Belo Horizonte, Minas Gerais, 30110-934, Brazil
Associao Paranaense de Cultura APC
Curitiba, Paraná, 80230-130, Brazil
Centro Digestivo de Curitiba
Curitiba, Paraná, 80430-160, Brazil
Hospital de Clnicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90035-903, Brazil
Hospital Ernesto Dornelles
Porto Alegre, Rio Grande do Sul, 90160-093, Brazil
Newdata Clinical Trials
Aracaju, Sergipe, 49075-000, Brazil
Pesquisare Saude
Santo André, São Paulo, 09080-110, Brazil
CPQuali Pesquisa Clinica Ltda
So Paulo, São Paulo, 01228-000, Brazil
London Digestive Disease Institute
London, Ontario, N6K 1M6, Canada
Hopital Maisonneuve-Rosemont d/b/a CIUSSS de l'Est-de-l'le-de-Montral
Montreal, Quebec, H1T 2M4, Canada
Clinique IMD
Montreal, Quebec, H3H 1E8, Canada
Zhongshan Hospital Xiamen University
Xiamen, Fujian, 361004, China
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450014, China
Binzhou Medical university hospital
Binzhou, Shandong, 256603, China
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, 315010, China
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, 310018, China
PreventaMed, s.r.o.
Olomouc, 779 00, Czechia
Nemocnice Slany
Slaný, 27401, Czechia
Groupe Hospitalier Ambroise Pare - Institut des MICI
Neuilly, Hauts De Seine, 92200, France
CHU Saint Etienne - Hpital Nord
Saint-Étienne-de-Montluc, Pays de la Loire Region, 42055, France
CHU Clermont Ferrand - Hôpital d'Estaing
Clermont-Ferrand, Puy De Dome, 63000, France
Centre hospitalier Lyon Sud
Pierre-Bénite, Rhone, 69495, France
Universitaetsklinikum Frankfurt Goethe-Universitaet
Frankfurt am Main, Hesse, 60590, Germany
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Emilia-Romagna, 00168, Italy
Fondazione Poliambulanza Istituto Ospedaliero
Brescia, Lombardy, 25124, Italy
ASST Rhodense, Rho Memorial Hospital
Rho, Lombardy, 20017, Italy
Istituto Clinico Humanitas
Rozzano, Lombardy, 20089, Italy
I.R.C.C.S Policlinico San Donato
San Donato Milanese (MI), Lombardy, 20097, Italy
Ospedale Mauriziano Umberto I
Turin, Piedmont, 10128, Italy
Kokikai Tsujinaka Hospital Kashiwanoha
Kashiwa-shi, Chiba, 277-0871, Japan
Fukuoka University Hospital
Fukuoka, Fukuoka, 814-0180, Japan
NHO Fukuyama Medical Center
Fukuyama-shi, Hiroshima, 720-8520, Japan
NHO Kanazawa Medical Center
Kanazawa, Ishikawa-ken, 920-8650, Japan
Takamatsu Red Cross Hospital
Takamatsu, Kagawa-ken, 760-0017, Japan
NHO Osaka National Hospital
Osaka, Osaka, 540-0006, Japan
Saga University Hospital
Saga, Saga-ken, 849-8501, Japan
Shinseikai Sai Gastroenterology, Proctology
Fujidera-shi, 583-0027, Japan
Kojunkai Daido Clinic
Nagoya, 457-8511, Japan
Centro Medico Clinico Quirurgico Especializado en Investigacion
Tlajomulco de Zúñiga, Jalisco, 45645, Mexico
Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan
Mérida, Yucatán, 97130, Mexico
Centrum Medyczne "Medis"
Bydgoszcz, 85-229, Poland
Clinsante S.C. Osrodek Badan Klinicznych
Bydgoszcz, 85-794, Poland
Centrum Medyczne Lukamed Joanna Luka
Chojnice, 89-600, Poland
Vita Longa Sp. z o.o.
Katowice, 40-748, Poland
MZ Badania Slowik Zymla Sp.j.
Knurów, 44-190, Poland
Allmedica Badania Kliniczne sp. z o.o. sp.k.
Nowy Targ, 34-400, Poland
SOLUMED Centrum Medyczne
Poznan, 60-529, Poland
NSZOZ Termedica Centrum Badan Klinicznych
Poznan, 60-681, Poland
Clinical Research Center Spka z ograniczon odpowiedzialnoci Medic-R Sp.k.
Poznan, 61-731, Poland
Velocity Skierniewice Sp. z o.o
Skierniewice, 96-100, Poland
Twoja Przychodnia-Szczecinskie Centrum Medyczne
Szczecin, 71-434, Poland
Centrum Zdrowia MDM
Warsaw, 00-189, Poland
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych Administracji
Warsaw, 02-507, Poland
Provita Poliklinika sp. z o.o
Warsaw, 02-647, Poland
Medon Clinical Research sp. z o.o
Warsaw, 02-679, Poland
Medical Network Spka z o. o., WIP Warsaw IBD Point Profesor Kierkus
Warsaw, 04-501, Poland
Przychodnia VISTAMED
Wroc?aw, 53-149, Poland
ETG Zamosc
Zamość, 22-400, Poland
Yonsei University Wonju Severance Christian Hospital
Wŏnju, Gangwon-do, 26426, South Korea
Inje university Haeundae Paik Hospital
Busan, 48108, South Korea
The Catholic University of Korea Daejeon ST. Mary?s Hospital
Daejeon, 34943, South Korea
Chosun University Hospital
Gwangju, 61453, South Korea
Kangbuk Samsung Hospital
Seoul, 03181, South Korea
The Catholic University of Korea Eunpyeong St. Mary's Hospital
Seoul, 03312, South Korea
Asan Medical Center.
Seoul, 05505, South Korea
Samsung Medical Center
Seoul, 06351, South Korea
Chung-Ang University Hospital
Seoul, 06973, South Korea
Guy's Hospital
London, Greater London, SE1 9RT, United Kingdom
King's College Hospital
London, Greater London, SE5 9RS, United Kingdom
Royal Liverpool University Hospital
Liverpool, Merseyside, L7 8YE, United Kingdom
John Radcliffe Hospital
Oxford, Oxfordshire, OX3 9DU, United Kingdom
Addenbrook'es Hospital
Cambridge, CB2 0QQ, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Trials
Genentech, Inc.
Central Study Contacts
Reference Study ID Number: GA45977 https://forpatients.roche.com/
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 15, 2025
First Posted
May 18, 2025
Study Start
September 29, 2025
Primary Completion (Estimated)
August 25, 2027
Study Completion (Estimated)
October 31, 2028
Last Updated
May 4, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will share
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing